Biogen Inc. stock underperforms Tuesday when compared to competitors
The stock's fall snapped a seven-day winning streak.
Sage moved to Underperform at BofA; says Biogen’s buyout impact has passed
Sage Therapeutics (NASDAQ:SAGE) stock drops as Bank of America issues an Underperform rating citing an end to Biogen's (BIIB) ...
Piper Sandler Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM)
Piper Sandler analyst David Amsellem reiterated a Buy rating on Axsome Therapeutics (AXSM – Research Report) today and set a price target of ...
Zacks Investment Research on MSN20h
IONS/AZN Get FDA Nod for Amyloidosis Drug, Wainzua in Europe
Ionis Pharmaceuticals IONS announced that the European Commission (“EC”) has approved Wainzua (eplontersen) for treating ...
Biogen Inc.: Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with late AMRAMR is a leading cause of kidney transplant loss, with approximately ...
Biogen announces initiation of dosing in TRANSCEND
Biogen (BIIB) announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the efficacy and ...
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with ...
Regina woman is living proof of 'breakthrough' ALS drug now approved in Canada
A Regina mother who was one of the first ALS patients to test a new treatment is now celebrating its accelerated approval in Canada for adults with an ultra-rare form of the disease.